Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Diseases|Metastases, Neoplasm
Interventions: DRUG: BNP7787|DRUG: Placebo
Sponsor: BioNumerik Pharmaceuticals, Inc.
Collaborators: Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.